Meteorologist Receives Cheerful Welcome Back to Newsroom Following 2-Month Absence for Traumatic Brain Injury
CBS News joyfully welcomed Lonnie Quinn back to the office after his two-month absence
The meteorologist sustained a traumatic brain injury in March, which required two months of rest
He initially thought it was a concussion, and encouraged his viewers to be cautious with the recovery for any head injury
The CBS New York newsroom is celebrating the return of its chief meteorologist after a significant brain injury.
Lonnie Quinn, the lead weather anchor on WCBS-TV who also appears on CBS Evening News, sustained a traumatic brain injury in March and needed roughly two months of rest in order to recover.
He made his joyful return to the office on Monday, May 5 — and now CBS is sharing a glimpse into the special moment his coworkers welcomed him back.
In a video posted on Tuesday, CBS New York captured employees embracing Quinn, 61, and clapping as he made his way through the office after months away. One person even waved a "number 1" foam finger in the background of the heartwarming scene.
Related: Meteorologist Returns to Work After Nearly 2 Months Off the Air Due to Traumatic Brain Injury
"It was a very major head injury," Quinn said, per the station. "Once the MRI came back, that's when the doctors came in and said 'Whoa, whoa, whoa. This is actually a traumatic brain injury, not just a concussion. You've got to be out of work for six to eight weeks, rest and relaxation.' "
Quinn initially thought he had a concussion after he "took a wallop on my head" in March, he said on Monday's broadcast. He then went to the hospital just to confirm there was no internal bleeding in his brain, and his negative CT scan meant he could go home.
For a short time afterward, he lost vision out of his left eye. "There was no way I could go on," he recalled. But it came on quickly and dissipated just as fast, lasting about 15 minutes."
After Quinn completed the newscast that day, a CBS news director — "who really looks out for her people," he said — insisted Quinn couldn't drive home and that he needed to go to the hospital.
Rob Marciano/Instagram Lonnie Quinn.
Lonnie Quinn.
Related: CBS Evening News Returns to N.Y.C. with a Twist: Inside the Making of a New, Dual-Anchor Broadcast (Exclusive)
Never miss a story — sign up for PEOPLE's free daily newsletter to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
At the hospital, where he underwent further imaging with an MRI, Quinn discovered he didn't just have a concussion. On Monday's broadcast, Quinn cautioned his viewers to take proper care in the event of a head injury, and to take doctors' advice seriously.
"When you bang your head, your brain recovers nicely, but it only recovers while the body is sleeping," he said.
"Listen, I missed you guys more than you know," he said to his coworkers. "I mean, this is a business where we're kind of connected to what we do, and I'm certainly connected with you guys."
Read the original article on People
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 days ago
- Medscape
MRI-Led Surveillance Stratifies Prostate Cancer Risk
In a cohort study of patients with prostate cancer, MRI-led risk-adapted active surveillance demonstrated effectiveness in risk stratification. The approach showed that MRI visibility and the presence of secondary Gleason pattern 4 at baseline were associated with higher rates of progression and treatment initiation. METHODOLOGY: Researchers analysed 1150 patients who started active surveillance between February 2000 and July 2023, including those with a Gleason score (GS) ≤ 3 + 4, prostate-specific antigen (PSA) < 20 ng/mL, and at least two MRI scans. Participants underwent PSA testing three to four times in the first year, followed by biannual testing; MRI was performed at baseline and 12 months, with an additional MRI scan performed at 24 months for those with MRI-visible lesions at baseline. Patients were stratified into four groups on the basis of baseline risk factors, including GS (3 + 3 vs 3 + 4) and MRI visibility ("non-visible disease" vs "visible disease"). The primary outcome was event-free survival, with an event defined as the detection of GS ≥ 4 + 3 or the initiation of any prostate cancer treatment. The median follow-up duration was 64 months per person overall and 72 months for 732 patients without an event. At baseline, 64% of patients had GS 3 + 3 and 36% had GS 3 + 4; 49% of those with GS 3 + 4 had MRI-visible disease. TAKEAWAY: Event-free survival rates varied significantly on the basis of the risk group, with 5-year rates of 91% for non-visible GS 3 + 3, 71% for MRI-visible GS 3 + 3, 71% for non-visible GS 3 + 4, and 44% for MRI-visible GS 3 + 4 disease. Among 487 patients who underwent follow-up biopsies, histological upgrade to GS ≥ 4 + 3 occurred in 67 patients; non-visible GS 3 + 3 cases had 5- and 10-year rates of 1.2% and 6.1%, respectively, for histological progression to GS ≥ 4 + 3, while the rates were 17% and 43% for those with MRI-visible GS 3 + 4 disease at baseline, respectively. Progression to nodal or bone metastases was observed in 10 patients, occurring only in those who had declined recommended follow-up MRI and/or biopsies. The 10-year rate of commencing treatment was 28% for those with non-visible GS 3 + 3 disease vs 85% for those with MRI-visible GS 3 + 4 disease and 46% for those with non-visible GS 3 + 4 disease vs 54% for those with MRI-visible GS 3 + 3 disease. IN PRACTICE: "Results from our cohort suggest that AS [active surveillance] patients can be monitored safely with MRI, and the decision to biopsy was based on MRI findings and PSA changes. Prospective, multicentre, clinical trials are required and currently being designed to further evaluate this approach," the authors wrote. SOURCE: This study was led by Cameron Englman, Division of Surgery & Interventional Science, University College London, London, England. It was published online on May 27, 2025, in European Urology . LIMITATIONS: Compared with time-based biopsy protocols, the MRI-led risk-adapted approach may underestimate histological progression. Additionally, as a cohort study without a strict protocol, practice evolved alongside contemporary pathology and radiology standards, with MRI quality, reporting standards, and the definition of radiological progression varying over time, particularly improving after the adoption of the PRECISE recommendations in 2016. DISCLOSURES: This study did not receive any specific funding. Several authors reported receiving consulting fees and grants and having other ties with various sources.
Medscape
2 days ago
- Medscape
Radiology Workforce Shortages Impacting Cancer Care
A chronic shortage of radiologists and oncologists is putting patients in the UK at risk, a new report found. The annual workforce census by the Royal College of Radiologists (RCR) warned that the safe delivery of NHS cancer care is becoming 'increasingly impossible' due to an escalating shortfall of doctors coupled with rising demand for care. In 2024, the UK had a 29% shortfall of clinical radiologists, with regional gaps ranging from 25% in Scotland to 32% in Wales. The workforce grew by 4.7% that year — less than in 2023, when it increased by 6.3%. The college forecasts the radiologist shortfall will reach 39% by 2029. Oncology Under Strain Clinical oncologists are also in short supply, with a current 15% gap expected to rise to 19% by 2029. This is despite a 5.4% increase in the workforce in 2024—the strongest growth since 2018. The RCR reported that 23% of cancer centres were experiencing recruitment freezes, making it harder to meet growing demand. Demand Continues to Outpace Capacity The shortages threaten the government's plans to cut waiting times and improve cancer outcomes. In 2024, demand for computerised tomography (CT) and magnetic resonance imaging (MRI) grew by 8%, but workforce growth did not keep pace. Every radiology leader surveyed last year reported delays to diagnostic scans caused by staff shortages. Nine in 10 radiology team leaders reported that patients were waiting longer to start treatment, while seven in 10 expressed concern that staff shortages were putting patient safety at risk – down slightly from 85% in 2023. Chronic problems such as workforce shortages, reporting backlogs, and staff vacancies remain too high, according to Dr Robin Proctor, the RCR's m edical director responsible for professional practice and clinical radiology. Consultants Leaving Earlier Staff retention is worsening, with experienced consultants leaving the NHS at younger ages. In 2024, the median age of consultant clinical radiologists leaving the NHS workforce was 50 – down from 56 in 2020. Four in five (79%) of leavers were under 60, and two in five (42%) were under 45. Clinical oncologists followed a similar trend. Their median exit age dropped to 54, from 57 in 2023 and 59 in 2022. Nearly 76% of leavers were under 60, and 26% were under 45. One consultant clinical oncologist told the college that delays in scans and treatment were resulting in missed or late cancer diagnoses. Some patients' conditions were deteriorating or reaching a stage where treatment was no longer possible. Changing Work Practices 'Working conditions and ways of working need to change if we are to address this problem and meet the growing demand for our expertise,' Proctor said. The RCR has called on the government to invest in training and recruitment. In 2024, the NHS spent an estimated £325 million on temporary radiology staff. The cost of outsourcing had doubled since before the COVID-19 pandemic and had surged by almost a quarter in the past year. The RCR estimated that increasing radiology trainee numbers by 50% could eliminate three-quarters of the current shortfall and save the NHS £460 million over the next 10 years. 'Patients are being failed by a chronic lack of radiologists and oncologists,' said RCR president Dr Katharine Halliday. 'The longer we delay action, the worse it gets,' she added.
Yahoo
2 days ago
- Yahoo
Paramount chair Shari Redstone confirms thyroid cancer diagnosis
Paramount Global chair Shari Redstone was diagnosed with thyroid cancer earlier this spring, a spokesperson for Redstone said in a statement to Reuters on Thursday. After experiencing fatigue and other symptoms, Redstone sought medical help about two months ago and was diagnosed with thyroid cancer the next day. While surgeons removed her thyroid gland, some cancer cells remained as they had spread to her vocal cords, according to the New York Times, which first reported the news on Thursday. 'She is maintaining all professional and philanthropic activities throughout her treatment, which is ongoing. She and her family are grateful that her prognosis is excellent,' Redstone's spokesperson Molly Morse said. Redstone kept her diagnosis private, sharing it only with a tight circle of relatives, close friends, and advisers including David Ellison, the Skydance head and tech heir, whose company is set to purchase Paramount and the Redstone family's stake, NYT added. The diagnosis comes against the backdrop of Paramount preparing for an $8.4 billion merger with Skydance Media, which still requires FCC approval. The company also entered mediation to try and settle a lawsuit by President Donald Trump against CBS, reportedly offering $15 million to settle.
